Business Description
Atrium Therapeutics is a San Diego-based company founded in 2025 that develops gene-silencing treatments aimed at heart muscle diseases caused by genetic mutations. Its two lead programs target specific faulty genes responsible for rare inherited heart conditions, with the goal of addressing the root cause of these diseases rather than just managing symptoms. The company is also building a broader pipeline to tackle other genetic heart disorders.
